Interpace Biosciences targets Nasdaq uplisting with 1-for-5 reverse stock split
Reuters2026/08/27 12:34- Interpace Biosciences set a 1-for-5 reverse stock split effective Aug. 27 to support a proposed Nasdaq uplisting.
- Shares to trade split-adjusted on OTCID at the open Aug. 27; ticker to switch temporarily to IDXGD for 20 sessions.
- Outstanding shares to drop to about 5,500,000 from about 27,700,000; authorized share count unchanged.
- Nasdaq bid-price compliance is the primary goal; additional listing hurdles remain, including a $15 million public float threshold.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Delta Electronics (Thailand)'s Recent Selloff Presents Accumulation Opportunity -- Market Talk
The data center construction boom may increase inflationary pressure, and the Reserve Bank of Australia may be forced to maintain high interest rates.
The data center construction boom in Australia may lead to demand exceeding the supply capacity of the economy, which could push up inflation and force the Reserve Bank of Australia to maintain higher interest rates.
Reliance step-down unit Roptonal dissolves in Cyprus with effect Aug. 18, 2026
Crypto prices
More
